SEARCH

SEARCH BY CITATION

References

  • 1
    National Center for Health Statistics. Health, United States, 2006. With Chartbook on Trends in the Health of Americans. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2006. Available at: http://www.cdc.gov/nchs/data/hus/hus06.pdf. Accessed June 6, 2007.
  • 2
    Ong KL, Cheung BM, Man YB, et al. Prevalence, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:6975.
  • 3
    Office of the Assistant Deputy Under Secretary for Health for Policy and Planning. VHA Enrollment, Patients and Expenditures. Washington, DC: U.S. Department of Veterans Affairs Intranet Site; 2007. Available at: http://vaww.va.gov/vhaopp/default.htm. Accessed June 6, 2007.
  • 4
    Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2003;360:19031913.
  • 5
    MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765774.
  • 6
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:25342544.
  • 7
    Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:15271535.
  • 8
    Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J Hypertens. 2003;21:10551076.
  • 9
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 10
    Moser M, Franklin SS. Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris Interactive. J Clin Hypertens. 2007;9:316323.
  • 11
    The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:25602572.
  • 12
    VHA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension in the Primary Care Setting. Washington, DC: Office of Quality and Performance and the Veteran Affairs and Department of Defense Development Work Group, Veterans Health Administration, Department of Veterans Affairs; May 1999. Update 2004.
  • 13
    Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Sixth Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1997;157:24132446.
  • 14
    VHA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension in the Primary Care Setting. Washington, DC: Office of Quality and Performance and the Veteran Affairs and Department of Defense Development Work Group, Veterans Health Administration, Department of Veterans Affairs; 1999.
  • 15
    Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1993;153:154183.
  • 16
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 17
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239246.
  • 18
    Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48:846852.
  • 19
    Stafford RS, Monti V, Furberg CD, et al. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension. 2006;48:213218.
  • 20
    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:16841689.
  • 21
    Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:15451553.
  • 22
    Berlowitz DR, Cushman WC, Glassman P. Hypertension in adults across age groups. JAMA. 2005;294:29702971; author reply 2971–2972.
  • 23
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393404.
  • 24
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 25
    Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141147.
  • 26
    Materson BJ, Reda DJ, Cushman WC, et al. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens. 1995;9:791796.
  • 27
    Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:14011409.
  • 28
    Furmaga EM, Glassman PA, Cunningham FE, et al. Reducing the use of short-acting nifedipine by hypertensives using a pharmaceutical database. In: HenriksenK, BattlesJB, MarksES, LewinDI, eds Advances in Patient Safety: From Research to Implementation. Vol. 3, Implementation Issues. AHRQ Publication No. 05-0021-3. Rockville, MD: Agency for Healthcare Research and Quality; 2005:277289.
  • 29
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:19671975.
  • 30
    Lopez J, Meier J, Cunningham F, et al. Antihypertensive medication use in the Department of Veterans Affairs. Am J Hypertens. 2004;17:10951099.
  • 31
    Fretheim A, Håvelsrud K, MacLennan G, et al. (2007) The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis. PLoS Med. 4: e232. doi: 10.1371/journal.pmed.0040232.
  • 32
    Jha AK, Perlin JB, Kizer KW, et al. Effect of the transformation of the Veterans Health Care System on the quality of care. N Engl J Med. 2003;348:22182227.
  • 33
    Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education. Ann Intern Med. 2006;145:165175.